drugset
drugset / Trial / NCT06331728

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001

NCT06331728 ↗

Phase 1 Completed 32 enrolled IgGenix Australia Pty Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this randomized, double-blind, placebo-controlled, single ascending dose clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IGNX001 in peanut-allergic adults and older Adolescents.

Timeline

Start
2024-09-01
Primary completion
2025-11-06
Completion
2025-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject IGNX001 Unknown — Subcutaneous

Indications

food allergy